MANKIND PHARMA
Back to Balance Sheet
|
MANKIND PHARMA Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹4,687 Cr | ₹7,420 Cr | ₹187 Cr | ₹199 Cr | ₹169 Cr |
What is the latest Total Non-Current Liabilities ratio of MANKIND PHARMA ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2026 | ₹4,687 Cr |
| Mar2025 | ₹7,420 Cr |
| Mar2024 | ₹187 Cr |
| Mar2023 | ₹199 Cr |
| Mar2022 | ₹169 Cr |
How is Total Non-Current Liabilities of MANKIND PHARMA Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹4,687 Cr | -36.84 | |
| Mar2025 | ₹7,420 Cr | 3,860.66 | |
| Mar2024 | ₹187 Cr | -5.97 | |
| Mar2023 | ₹199 Cr | 18.12 | |
| Mar2022 | ₹169 Cr | - | |
Compare Total Non-Current Liabilities of peers of MANKIND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MANKIND PHARMA | ₹103,274.8 Cr | 9.6% | 1% | -6.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹422,283.0 Cr | 0.9% | -5% | 3.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹251,611.0 Cr | 3.6% | -1.4% | 37.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹175,182.0 Cr | 1.7% | -6.7% | 28% | Stock Analytics | |
| CIPLA | ₹109,063.0 Cr | 2.8% | -3.9% | -17.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹108,926.0 Cr | 5.4% | 8.7% | 1.6% | Stock Analytics | |
MANKIND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MANKIND PHARMA | 9.6% |
1% |
-6.2% |
| SENSEX | -0.3% |
-1.6% |
-12.3% |
You may also like the below Video Courses